Stockscreener 앱 받기
160.20
2.64%
4.12
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research
The Zacks Analyst Blog Highlights Eli Lilly, Novartis, Johnson & Johnson and AbbVie - Zacks Investment Research
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential - Zacks Investment Research
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss - Zacks Investment Research
Top Analyst Reports for Intel, Novartis & Itau Unibanco - Zacks Investment Research
Novartis AG : UBS sticks Neutral - marketscreener.com
Novartis MS Pill Trials Trigger Analyst Skepticism on Peak Sales - Bloomberg.com
Novartis AG : Gets a Neutral rating from RBC - marketscreener.com
Novartis AG : Gets a Neutral rating from Barclays - marketscreener.com
Novartis: Strong Drug Growth Faces A Tougher Test As Patent Losses And Pipeline Setbacks Mount - Seeking Alpha
Novartis Reports Positive Results from Late-stage Studies for Remibrutinib - marketscreener.com
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity - Yahoo Finance
Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple SclerosisSlideshow - Seeking Alpha
Novartis AG Remibrutinib in MS Investor Call Transcript - GuruFocus
Novartis AG (NVS) Stock Down 3.3% but Still Overvalued -- GF Score: 75/100 - GuruFocus
Novartis AG : RBC is Neutral - marketscreener.com
Novartis Multiple Sclerosis Pill Missed Expectations in Key Study - Bloomberg.com
Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib - Reuters
Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study - Bloomberg.com
Novartis AG Stock (NVS) Moved Down by 3.61% on Oct 23: Facts Behind the Movement - TradingKey
Novartis AG Estimates – BX:NOT - TradingView
Novartis AG expected to post earnings of $2.29 a shareEarnings Preview - TradingView
AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy - Zacks Investment Research
Novartis AG Lobbying Profile, 2004 - OpenSecrets
Earnings Preview: Novartis AG to Report Financial Results on October 27 - Moomoo
Novartis (NVS) Gains European Commission Approval for Cosentyx i - GuruFocus
European Commission OKs Novartis' Cosentyx for Treatment of Polymyalgia Rheumatica - marketscreener.com
Novartis receives European Commission approval for Cosentyx(R) in polymyalgia rheumatica (PMR) - marketscreener.com
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) - GlobeNewswire
Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR) - Yahoo Finance
Novartis AG Bills, 2012 - OpenSecrets
Novartis ranks #19 in TIME and Statista’s World’s Best Companies 2026 - Novartis
Novartis AG : UBS gives a Neutral rating - marketscreener.com
GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth - Zacks Investment Research
Novartis AG (NVS) Options ChainYahoo Finance - Yahoo! Finance Canada
Enterprise value to revenue forward of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView
Novartis: The Sell-Off Creates An Attractive Entry Point (NYSE:NVS) - Seeking Alpha
Novartis Has Five Fast-Growing Drugs, but Is Its Valuation Asking Too Much? - Yahoo Finance
Novartis Discontinues Mid-Stage Fabhalta Trial in Lupus Nephritis for Strategic Reasons - Yahoo Finance
Novartis ends mid-stage Fabhalta trial targeting serious kidney condition - Reuters
Novartis AG (NVSD.BA) valuation measures and financial statistics - Yahoo Finance Australia
Novartis AG (NOVN.VI) interactive stock chart - Yahoo Finance UK
Novartis AG (NVS) Stock forecasts - Yahoo Finance UK
RBC Capital Remains a Hold on Novartis AG (NOVN) - The Globe and Mail
Novartis AG (NVS) Stock Forecasts - Yahoo! Finance Canada
Novartis wins Rhapsido approval as Bank of America keeps CHF 150 target for Novartis stock - ad-hoc-news.de
Novartis AG : RBC is Neutral - www.marketscreener.com
IgA Nephropathy Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - StreetInsider
Novartis AG Stock (NVS) Moved Up by 3.00% on Oct 15: Drivers Behind the Movement - TradingKey
2.61%
자본화:
|
볼륨(24시간):